Antifungal susceptibility testing. New technology and clinical applications.
about
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans.Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species.Proteomic characterization of human proinflammatory M1 and anti-inflammatory M2 macrophages and their response to Candida albicans.Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcomeDetermination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Antifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda.Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study.Pharmacological assessment of the medicinal potential of Acacia mearnsii De Wild.: antimicrobial and toxicity activities.Combination treatment of invasive fungal infections.Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.Antifungal resistance and new strategies to control fungal infections.Integrated proteomics and genomics strategies bring new insight into Candida albicans response upon macrophage interaction.In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis.Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.In vitro evaluation of antifungal susceptibility and keratinase, elastase, lipase and DNase activities of different dermatophyte species isolated from clinical specimens in Iran.
P2860
Q30452376-A78102E6-46DF-4F58-BB73-FBBF27B31649Q30452998-ED77883F-AB8E-48E7-8A75-B1AA43F55766Q33714175-E61197DC-23EA-4578-84AE-6FF432DDA962Q33938166-AF12DC3B-5D1D-4052-8A67-998FC67931A7Q34041801-9A8E0374-8D3B-49CD-9FCE-684EC41A8D9EQ34142406-43E95303-3129-47F9-8CB0-B8E1A8C4AD87Q34774346-5FF3DACB-0E65-4F02-9196-8933BC0525DAQ35136446-6838EEFE-230C-4553-9E49-3C5280C66656Q35598567-108CCBEE-BDB7-45FB-97AD-B93C5CF5E5E0Q35745822-5F881AE4-70FE-48C8-8F01-63375ED2367EQ35848519-D969E073-7571-47A0-8005-A5B8EC35C3F9Q35899223-B7DBC061-0758-442C-A9F8-EA9161DA7720Q35933900-18CF7DF7-3240-4256-86E9-33ABCD5F095AQ36011378-DEEE1331-D9CE-40AB-939A-DA984231AACCQ37576369-73528888-5463-48AE-9FAF-8FA4765F0EABQ39665314-9C2FE439-553E-4F95-B9E6-BABB11373E80Q39751373-26745869-EF3B-4895-A6B8-8386A8F03DEDQ40197295-4ED31A91-C548-48F2-A139-C7EF90A7F43DQ42116450-989FC881-0C9B-455A-AF76-FBEAA1B9C2BCQ42561331-AE5878DE-6D42-4A48-9ACE-FF36E69BB53DQ45002264-A0CD8029-AD2E-4444-9469-F395112034DEQ46533883-A4DD9011-88A5-449B-BF94-1C2D3BE7672F
P2860
Antifungal susceptibility testing. New technology and clinical applications.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antifungal susceptibility testing. New technology and clinical applications.
@ast
Antifungal susceptibility testing. New technology and clinical applications.
@en
Antifungal susceptibility testing. New technology and clinical applications.
@nl
type
label
Antifungal susceptibility testing. New technology and clinical applications.
@ast
Antifungal susceptibility testing. New technology and clinical applications.
@en
Antifungal susceptibility testing. New technology and clinical applications.
@nl
prefLabel
Antifungal susceptibility testing. New technology and clinical applications.
@ast
Antifungal susceptibility testing. New technology and clinical applications.
@en
Antifungal susceptibility testing. New technology and clinical applications.
@nl
P1476
Antifungal susceptibility testing. New technology and clinical applications.
@en
P2093
P304
P356
10.1016/S0891-5520(05)70192-6
P577
2001-12-01T00:00:00Z